| 生物活性 |
Gypenoside XLIX is a multifunctional bioactive compound isolated from Gynostemma pentaphyllum with a Ka value of 1.58 μM for binding to SIRT1; as a PPAR-α activator, it inhibits TLR4-mediated activation of the NF-κB signaling pathway by activating the Sirt1/Nrf2 signaling pathway, reduces ROS accumulation, and alleviates hepatic inflammatory injury in mice with septic liver disease; it targets SIRT1 to block YAP-NLRP3 activation and ameliorate sepsis-induced cardiomyopathy; it inhibits apoptosis, pyroptosis, autophagy, lipid peroxidation, pro-inflammatory cytokines, and anti-inflammatory factors; it alleviates sepsis-induced splenic injury by inhibiting inflammation and oxidative stress, mitigates sepsis-associated encephalopathy by targeting PPAR-α, prevents acute kidney injury by inhibiting IGFBP7/IGF1R-mediated programmed cell death and inflammation, and inhibits cytokine-induced expression and activity of vascular cell adhesion molecule-1 in human endothelial cells; it can be used for research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis, and chronic inflammation. |
体外研究 (In Vitro) |
Gypenoside XLIX (0-80 μM) 在 10、20、40 和 80 μM 的浓度降低 RAW264.7 细胞的活力,在 5 μM 浓度下无显著影响。 Gypenoside XLIX (40 μM) 可通过降低 P-IκBα 和 P-P65 水平、恢复 IκBα 水平,抑制 RAW264.7 细胞中由 LPS (MS-X54539) 激活的 NF-κB 信号通路,可通过上调 PPAR-α 蛋白水平激活 LPS 刺激的 RAW264.7 细胞中的 PPAR-α。 Gypenoside XLIX (40 μM; 1 h pre-incubation) 可通过上调 Nrf2、HO-1 及 NQO1 的蛋白水平激活 LPS 刺激的 RAW264.7 细胞中的抗氧化 Nrf2 通路,从而减轻氧化应激。 Gypenoside XLIX (40 μM; 1 h pre-incubation) 可通过降低 NLRP3、ASC、Caspase1 P20、GSDMD 和 IL-1β 蛋白水平,抑制 NLRP3 炎症小体通路并减轻 LPS 刺激的 RAW264.7 细胞的焦亡。 Gypenoside XLIX (32 μM; 12 h) 可激活 Sirt1/Nrf2 信号通路,减少 ROS 的生成,并在 LPS/ATP (MS-D18391) 刺激的 MLE-12 细胞中抑制 NLRP3 炎症小体的激活。 Gypenoside XLIX (3.125-100 μM) 可高亲和力直接结合重组 SIRT1 蛋白,通过 SPR 测得的 Kd 值为 1.58 μM,在 H9C2 大鼠心肌细胞中稳定 SIRT1 蛋白,抵御热诱导的降解。 Gypenoside XLIX (40 μM; 24 h) 以 SIRT1 依赖的方式缓解 LPS 诱导的 H9C2 大鼠心肌细胞炎症与氧化应激,降低促炎细胞因子表达、氧化应激标志物水平及 NLRP3 炎症小体的激活,促进细胞中 YAP 的磷酸化、去乙酰化及蛋白酶体降解。 Gypenoside XLIX (40 μM) 可通过增强 K27 连接的泛素化作用,在过表达 YAP 的 H9C2 大鼠心肌细胞中促进 NLRP3 的转录后蛋白酶体降解,逆转 YAP 诱导的 NLRP3 上调。 Gypenoside XLIX (20-40 μM) 可降低小鼠小胶质细胞 BV-2 的存活率。 Gypenoside XLIX (10 μM; 12 h) 可降低 LPS 刺激的小鼠小胶质细胞 BV-2 中的 NO,ROS 生成,上调细胞中 PPAR-α 的表达,并抑制 p38 和 JNK MAPK 通路的激活,该效应部分依赖于 PPAR-α 的激活。 Gypenoside XLIX (10 μM; 12 h) 可降低 LPS 刺激的小鼠小胶质细胞 BV-2 中炎症蛋白 iNOS、COX-2 和 TLR4 的表达,激活细胞中的 Nrf2/Keap1 氧化应激反应通路,该效应依赖于 PPAR-α 的激活。 Gypenoside XLIX (10 μM; 12 h) 可通过调控凋亡蛋白的表达来降低 LPS 刺激的小鼠小胶质细胞 BV-2 的凋亡水平,该效应依赖于 PPAR-α 的激活。 Gypenoside XLIX (0-256 μM; 24 h) 可恢复经 Cisplatin (MS-E94993) 处理的 HK2 细胞的活力。 Gypenoside XLIX (0-128 μM; 24 h) 可降低 Cisplatin, 缺氧/复氧 (H/R) 诱导的 HK2 细胞中 KIM-1 蛋白及 KIM-1 mRNA 水平的升高,降低促炎细胞因子产生及 NF-κB 活化,抑制细胞坏死性凋亡与细胞凋亡。 Gypenoside XLIX (64 μM; overnight pre-incubation) 通过降低 IGFBP7 的表达及其与 IGF1R 的结合,在 Cisplatin 处理的 HK2 细胞中激活 IGF 通路。 Gypenoside XLIX (10-300 μM; 0.5-24 h) 可通过 PPAR-α 依赖通路抑制 TNF-α 诱导的人脐静脉内皮细胞 (HUVECs) 中 VCAM-1 启动子活性 (IC50 = 186.8 μM)、mRNA 表达、总蛋白表达、表面 VCAM-1 表达。
Western Blot Analysis
| Cell Line: |
LPS-stimulated RAW264.7 |
| Concentration: |
40 μM |
| Incubation Time: |
1 h (pre-incubation) |
| Result: |
Significantly reduced LPS-induced increases in P-IκBα, P-P65 protein levels. Reversed LPS-induced decreases in IκBα protein levels.\n Significantly increased Nrf2,, PPAR-α, HO-1 and NQO1 protein levels. Significantly reduced LPS-induced increases in NLRP3, ASC, Caspase1 P20, GSDMD, and IL-1β protein levels. |
Western Blot Analysis
| Cell Line: |
LPS-stimulated mouse microglial BV-2 cells |
| Concentration: |
10 μM (pretreated before LPS stimulation) |
| Incubation Time: |
12 h (pretreated before LPS stimulation) |
| Result: |
Increased PPAR-α protein expression relative to LPS-only treated cells. Reduced p-p38 and p-JNK protein expression relative to LPS-only treated cells. These effects were partially reversed by co-treatment with 5 μM PPAR-α inhibitor GW6471 (pretreated for 30 min before Gypenoside XLIX).\nReduced iNOS, COX-2, and TLR4 protein expression relative to LPS-only treated cells; these effects were reversed by co-treatment with 5 μM PPAR-α inhibitor GW6471 (pretreated for 30 min before Gypenoside XLIX).\nIncreased Nrf2 protein expression relative to LPS-only treated cells. Reduced Keap1 protein expression relative to LPS-only treated cells; these effects were reversed by co-treatment with 5 μM PPAR-α inhibitor GW6471 (pretreated for 30 min before Gypenoside XLIX).\nReduced Bax protein expression relative to LPS-only treated cells. Increased Bcl-2 protein expression relative to LPS-only treated cells; these effects were reversed by co-treatment with 5 μM PPAR-α inhibitor GW6471 (pretreated for 30 min before Gypenoside XLIX). |
Cell Viability Assay
| Cell Line: |
HK2 (human renal tubular epithelial cells) |
| Concentration: |
32 μM (pre-incubated before 24 h Cisplatin treatment); 64 μM (pre-incubated before 24 h Cisplatin treatment); 128 μM (pre-incubated before 24 h Cisplatin treatment) |
| Incubation Time: |
12 h (pre-incubation); 24 h (cisplatin treatment) |
| Result: |
Markedly restored HK2 cell viability in response to Cisplatin treatment. |
Western Blot Analysis
| Cell Line: |
HK2 (hypoxia/reoxygenation (H/R)-treated human renal tubular epithelial cells) |
| Concentration: |
64 μM (pre-incubated before H/R treatment) |
| Incubation Time: |
12 h (hypoxia); 6 h (reoxygenation) |
| Result: |
Downregulated H/R-induced increases in protein levels of RIPK1, RIPK3, and cleaved caspase-3. |
RT-PCR
| Cell Line: |
human umbilical vein endothelial cells (HUVECs) |
| Concentration: |
10-300 μM |
| Incubation Time: |
30 min pre-incubation before 5 h TNF-α stimulation |
| Result: |
Concentration-dependently decreased TNF-α-induced VCAM-1 mRNA overexpression (a ~3-fold increase in controls). |
Western Blot Analysis
| Cell Line: |
human umbilical vein endothelial cells (HUVECs) |
| Concentration: |
10-300 μM |
| Incubation Time: |
30 min pre-incubation before 5 h TNF-α stimulation |
| Result: |
Concentration-dependently decreased TNF-α-induced VCAM-1 protein overexpression (a ~3-fold increase in controls). |
ELISA Assay
| Cell Line: |
human umbilical vein endothelial cells (HUVECs) |
| Concentration: |
10-300 μM |
| Incubation Time: |
24 h pre-incubation before 8 h TNF-α stimulation |
| Result: |
Concentration-dependently decreased TNF-α-induced cell surface VCAM-1 expression, reducing control activity to 51.4 ± 3.7% at 300 μM. |
|
体内研究 (In Vivo) |
Gypenoside XLIX (40 mg/kg; i.p.; single dose/daily; 4 days) 可通过激活 Sirt1/Nrf2 信号通路来抑制 NF-κB/PPAR-α/NLRP3 通路,改善肝功能异常、减轻炎症反应、氧化应激、脂质蓄积及细胞焦亡、线粒体通路凋亡及过度线粒体自噬,从而显著缓解小鼠中由盲肠结扎和穿刺 (CLP) 诱导的急性肝损伤。 Gypenoside XLIX (10-40 mg/kg; i.p.; daily; 5 days) 呈剂量依赖性缓解脓毒症诱导的心肌病,其中 40 mg/kg 剂量的治疗效果最为显著,包括 80% 的存活率、炎症与氧化应激水平降低、心功能恢复,以及通过激活 SIRT1 抑制 YAP-NLRP3 通路。 Gypenoside XLIX (20 mg/kg; i.p.; daily; 4 days) 可通过降低 ROS 和 MDA 水平、增强抗氧化酶活性及调控促炎与抗炎介质的表达,显著减轻脓毒症雄性 BALB/c 小鼠中由 CLP 诱导的急性脾脏炎症和氧化应激。 Gypenoside XLIX (40 mg/kg; i.p.; daily; 5 days) 可通过激活 PPAR-α 缓解 CLP 诱导的 C57BL/6 小鼠中脓毒症相关性脑病,将生存率提升至 73.33%,同时减轻神经炎症、氧化应激、细胞凋亡及血脑屏障损伤,并恢复认知功能。 Gypenoside XLIX (25-100 mg/kg; i.p.; daily; 3 days) 可通过抑制肾脏炎症、坏死性凋亡、细胞凋亡以及 IGFBP7/IGF1R 通路失调,显著保护雄性 C57BL/6 小鼠免受 Cisplatin 、肾缺血再灌注诱导的急性肾损伤 (AKI),同时可显著降低血清肌酐、尿素氮 (BUN)、肾小管损伤评分,以及促炎症和细胞死亡标志物水平。
| Animal Model: |
BALB/c (male, 6 weeks old, 20-25 g CLP-induced sepsis model) |
| Dosage: |
40 mg/kg |
| Administration: |
i.p.; single dose/daily; 4 consecutive days |
| Result: |
Ameliorated the CLP-induced darkening of liver tissue and maintained the structural integrity of the liver; reduced the severity of hepatocyte vacuolar degeneration, necrosis, and architectural disarray, resulting in a liver structure that appeared more normal and orderly arranged. Significantly reduced the serum levels of the liver dysfunction biomarkers ALT and AST. Decreased the mRNA expression levels of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α, as well as the inflammatory mediator iNOS, while increasing the mRNA expression level of the anti-inflammatory cytokine IL-10. Significantly reduced the protein expression levels of TLR4 and iNOS. Increased the protein levels of IκBα in liver tissue and decreased the protein levels of p-p65, thereby inhibiting the activation of the NF-κB signaling pathway. Reduced the levels of MDA and the protein levels of CYP2E1 in liver tissue, while increasing the levels of T-AOC, CAT, and GSH, as well as the protein levels of Nrf2 and HO-1, also reduced the accumulation of ROS in the liver, thereby effectively alleviating oxidative stress-induced injury. Increased the protein levels of PPAR-α in liver tissue and reduced the number of lipid droplets (as detected by Oil Red O staining), thereby alleviating hepatic lipid accumulation. Reduced the protein expression levels of NLRP3, ASC, Caspase-1 p20, GSDMD, and IL-1β in liver tissue, thereby inhibiting the occurrence of hepatocyte pyroptosis. Iincreased the protein expression levels of Sirt1 and Nrf2 in lung tissue, thereby activating the Sirt1/Nrf2 signaling pathway. Significantly reduced the number of TUNEL-positive apoptotic cells in lung tissue; it decreased the protein expression of cleaved Caspase-3, Cytochrome c, and Bax, while increasing the protein expression of the anti-apoptotic marker Bcl-2. Reduced the protein expression levels of the mitochondrial autophagy-related markers Pink1, Parkin, and the LC3B II/I ratio, while increasing the protein expression of p62, thereby inhibiting excessive mitochondrial autophagy.
|
| Animal Model: |
C57BL/6 (male, 8 weeks old, cecal ligation and puncture surgery-induced sepsis) |
| Dosage: |
10 mg/kg; 20 mg/kg; 40 mg/kg |
| Administration: |
i.p.; daily; 5 days |
| Result: |
Increased survival rate, with significant improvement at 20 and 40 mg/kg. Significantly reduced sepsis model scores at 20 and 40 mg/kg. Significantly reduced cardiac wet-to-dry weight ratios at 20 and 40 mg/kg. Reduced serum creatine kinase (CK) and lactate dehydrogenase (LDH) levels at all three doses, with the most significant reduction at 40 mg/kg. Significantly mitigated CLP-induced body weight loss at 20 and 40 mg/kg. Significantly reduced cardiomyocyte disorganization, interstitial gap enlargement, and lymphocyte infiltration, with improved H&E staining and reduced histopathological scores at 40 mg/kg. Reduced left ventricular internal dimension in diastole/systole (LVIDd/LVIDs) ratio, increased left ventricular anterior wall thickness in diastole (LVAWd), left ventricular posterior wall thickness in diastole (LVPWd), fractional shortening (FS), and ejection fraction (EF) at 40 mg/kg compared to untreated mice, reversing ventricular dilation and systolic dysfunction. Reduced cardiac mRNA expression of pro-inflammatory cytokines IL-1β, IL-6, iNOS, and TNF-α, increased anti-inflammatory cytokine IL-10 mRNA expression, and reduced protein levels of iNOS, COX-2, and TLR4 at 40 mg/kg. Increased cardiac glutathione (GSH), catalase (CAT), and total antioxidant capacity (T-AOC) levels, reduced malondialdehyde (MDA) levels, reversed CLP-induced increases in Keap1 protein and decreases in Nrf2 protein, and reduced reactive oxygen species (ROS) levels at 40 mg/kg compared to untreated mice. Increased cardiac SIRT1 mRNA and protein expression, reduced total YAP protein levels, increased phosphorylated YAP levels, reduced acetylated YAP levels, and reduced NLRP3 protein expression at 40 mg/kg compared to untreated mice; promoted K27-linked polyubiquitination of NLRP3 to drive its degradation. |
| Animal Model: |
BALB/c (male, 6 weeks old, 20-25 g, CLP-induced sepsis) |
| Dosage: |
20 mg/kg |
| Administration: |
i.p.; daily; 4 days |
| Result: |
Mitigated CLP-induced splenic histopathological damage, restoring clear demarcation between red and white marrow with well-defined structures. Reduced CLP-induced splenic malondialdehyde (MDA) levels and increased catalase (CAT), glutathione (GSH), and total antioxidant capacity (T-AOC) levels in spleen tissue. Inhibited CLP-induced splenic reactive oxygen species (ROS) accumulation. Downregulated mRNA and protein levels of pro-inflammatory mediators iNOS, COX-2, TNF-α, IL-6, and IL-1β in spleen tissue. Upregulated mRNA levels of the anti-inflammatory cytokine IL-10 in spleen tissue. |
| Animal Model: |
C57BL/6 (6-8 weeks old; sepsis-associated encephalopathy induced by caecal ligation and puncture) |
| Dosage: |
40 mg/kg |
| Administration: |
i.p.; daily; 5 days |
| Result: |
Achieved a 73.33% survival rate in CLP-induced SAE mice. Reduced neurological deficit scores. Decreased brain water content. Mitigated cerebral cortex structural damage and reduced microglial hyperplasia. Increased time spent and distance travelled in the central area of the open field test; increased exploration of open arms in the elevated plus maze test; reduced escape latency in the Morris water maze test. Decreased Evans blue leakage, downregulated MMP9 protein expression, and upregulated claudin protein expression. Decreased mRNA expression of proinflammatory cytokines IL-1β, TNF-α, IL-6, and iNOS; increased mRNA expression of anti-inflammatory cytokine IL-10; downregulated protein expression of iNOS, COX-2, TLR4, and p-p65. Increased CAT activity, GSH content, and T-AOC activity; decreased MDA content and cerebral cortex ROS levels; upregulated Nrf2 protein expression and downregulated Keap1 protein expression. Reduced TUNEL-positive cells in the cerebral cortex; downregulated Bax and Cyto-C protein expression; upregulated Bcl-2 protein expression. Increased PPAR-α protein expression in brain tissue and downregulated activation of downstream MAPK signalling proteins (p-p38 and p-JNK). Reduced IBA1 protein expression in brain tissue. |
| Animal Model: |
C57BL/6 (male, 6-8 weeks old, Cisplatin/renal ischemia-reperfusion-induced AKI) |
| Dosage: |
25 mg/kg; 50 mg/kg; 100 mg/kg |
| Administration: |
i.p.; daily; 3 consecutive days (first dose 6 hours pre-cisplatin) |
| Result: |
Significantly suppressed the cisplatin-induced increase in serum creatinine and blood urea nitrogen levels. Significantly reduced tubular necrosis, dilation, and cast formation, with tubular injury scores decreased to levels significantly lower than the cisplatin group. Significantly reduced cisplatin-induced upregulation of KIM-1 mRNA and protein levels in kidney tissue. Significantly reduced the percentage of TNF-α-positive cells in kidney tissue, and suppressed cisplatin-induced upregulation of Tnf-α, Il-6, and Mcp-1 mRNA levels in kidney tissue. Significantly reduced cisplatin-induced increases in p-P65, RIPK1, RIPK3, and cleaved caspase-3 protein levels in kidney tissue. Reduced IGFBP7 mRNA and protein levels, and increased p-IGF1R protein levels in kidney tissue, while decreasing the binding of IGFBP7 to IGF1R. |
|